Back
Vertex Pharmaceuticals Quote, Financials, Valuation and Earnings
Buy
73
VRTX
Vertex Pharmaceuticals
Last Price:
456.97
Seasonality Move:
8.93%
7 Day Trial
ALL ACCESS PASS
$
7
Vertex Pharmaceuticals Price Quote
$456.97
+0.02 (+1.37%)
(Updated: May 25, 2024 at 6:44 AM ET)
Vertex Pharmaceuticals Key Stats
Buy
73
Vertex Pharmaceuticals (VRTX)
is a Buy
Day range:
$449.42 - $457.66
52-week range:
$320.01 - $457.66
Dividend yield:
0%
P/E ratio:
32.90
P/S ratio:
11.70
P/B ratio:
6.36%
Volume:
1M
Avg. volume:
1.1M
1-year change:
36.87%
Market cap:
$117.9B
Revenue:
$9.9B
EPS:
$15.41
How Much Does Vertex Pharmaceuticals Make?
-
How Much Are Vertex Pharmaceuticals's Sales Annually?
VRTX Revenues are $9.9B -
How Much Profit Does Vertex Pharmaceuticals's Make A Year?
VRTX net income is $3.6B
Is Vertex Pharmaceuticals Growing As A Company?
-
What Is Vertex Pharmaceuticals's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.13% -
What Is Vertex Pharmaceuticals's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0.57%
Vertex Pharmaceuticals Stock Price Performance
-
Did Vertex Pharmaceuticals Stock Go Up Last Month?
Vertex Pharmaceuticals share price went up by 14.02% last month -
Did VRTX's Share Price Rise Over The Last Year?
VRTX share price rose by 36.87% over the past 1 year
What Is Vertex Pharmaceuticals 52-Week High & Low?
-
What Is Vertex Pharmaceuticals’s 52-Week High Share Price?
Vertex Pharmaceuticals has traded as high as $457.66 over the past 52 weeks -
What Is Vertex Pharmaceuticals’s 52-Week Low Share Price?
Vertex Pharmaceuticals has traded as low as $320.01 over the past 52 weeks
Vertex Pharmaceuticals Price To Free Cash Flow
-
Is Vertex Pharmaceuticals Stock Overvalued?
Vertex Pharmaceuticals is trading at a price to free cash flow ratio of 34.24 -
Is Vertex Pharmaceuticals Stock Undervalued?
Vertex Pharmaceuticals EV to Free Cash Flow ratio is 30.97 -
What Is Vertex Pharmaceuticals’s Price Earnings Growth Ratio?
VRTX PEG ratio is 1.31 -
Is Vertex Pharmaceuticals Trading At A Premium To Earnings?
Vertex Pharmaceuticals EV to EBIT ratio is 22.40
Is It Risky To Buy Vertex Pharmaceuticals?
-
How Much Debt Does Vertex Pharmaceuticals Have?
Total long term debt quarterly is $0 -
How Much Cash Does Vertex Pharmaceuticals Have?
Cash and short term investments quarterly total is $10.2B -
What Is Vertex Pharmaceuticals’s Book Value Per Share?
Book value per share is 71.80
Is Vertex Pharmaceuticals Cash Flow Positive?
-
What Is VRTX Cash Flow From Operations?
Cash flow from operations (TTM) is $3.9B -
What Is Vertex Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$625M -
What Is Vertex Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$3.4B
Vertex Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
VRTX return on invested capital is 24.35% -
What Is Vertex Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is 18.66% -
What Is VRTX Return On Equity?
ROE is a measure of profitability and is 24.35%
Vertex Pharmaceuticals Earnings Date & Stock Price
-
What Is Vertex Pharmaceuticals's Stock Price Today?
A single share of VRTX can be purchased today for 456.95 -
What Is Vertex Pharmaceuticals’s Stock Symbol?
Vertex Pharmaceuticals trades on the S&P500 under the ticker symbol: VRTX -
When Is Vertex Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Vertex Pharmaceuticals is scheduled on August 1, 2024 -
When Is VRTX's next ex-dividend date?
Vertex Pharmaceuticals's next ex-dividend date is May 26, 2024 -
How To Buy Vertex Pharmaceuticals Stock?
You can buy Vertex Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Vertex Pharmaceuticals Competitors
-
Who Are Vertex Pharmaceuticals's Competitors?
Below is a list of companies who compete with Vertex Pharmaceuticals or are related in some way:
Vertex Pharmaceuticals Dividend Yield
Data Unavailable
Vertex Pharmaceuticals Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 56.51% | 17.28% |
| Revenue: | 13.3% | 4.28% |
Analyst Recommendations
| Buy Recommendations: | 14 |
|---|---|
| Hold Recommendations: | 9 |
| Sell Recommendations: | 2 |
| Price Target: | 462.81 |
| Upside from Last Price: | 1.28% |